Correction to: The Respiratory Syncytial Virus Prefusion F Protein Vaccine Attenuates the Severity of RSV-Associated Disease in Breakthrough Infections in Adults ≥60 Years of Age.
出版信息
Influenza Other Respir Viruses. 2024 Sep;18(9):e13364. doi: 10.1111/irv.13364.
Abstract
摘要
相似文献
1
Correction to: The Respiratory Syncytial Virus Prefusion F Protein Vaccine Attenuates the Severity of RSV-Associated Disease in Breakthrough Infections in Adults ≥60 Years of Age.对《呼吸道合胞病毒预融合F蛋白疫苗减轻60岁及以上成年人突破性感染中呼吸道合胞病毒相关疾病的严重程度》一文的更正
Influenza Other Respir Viruses. 2024 Sep;18(9):e13364. doi: 10.1111/irv.13364.
2
The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age.呼吸道合胞病毒预融合F蛋白疫苗可减轻60岁及以上成年人突破性感染中呼吸道合胞病毒相关疾病的严重程度。
Influenza Other Respir Viruses. 2024 Feb 3;18(2):e13236. doi: 10.1111/irv.13236. eCollection 2024 Feb.
3
Correction to "The Respiratory Syncytial Virus Prefusion F Protein Vaccine Attenuates the Severity of RSV-Associated Disease in Breakthrough Infections in Adults ≥60 Years of Age".对《呼吸道合胞病毒融合前F蛋白疫苗减轻60岁及以上成年人突破性感染中呼吸道合胞病毒相关疾病的严重程度》的勘误
Influenza Other Respir Viruses. 2025 Feb;19(2):e70088. doi: 10.1111/irv.70088.
4
The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged ≥60 years in Japan: results of a Markov model analysis.呼吸道合胞病毒预融合 F 蛋白疫苗对日本≥60 岁人群的潜在公共卫生影响：一项马尔可夫模型分析的结果。
Expert Rev Vaccines. 2024 Jan-Dec;23(1):303-311. doi: 10.1080/14760584.2024.2323128. Epub 2024 Mar 1.
5
Efficacy, immunogenicity and safety of respiratory syncytial virus prefusion F vaccine: systematic review and meta-analysis.呼吸道合胞病毒融合前 F 疫苗的疗效、免疫原性和安全性：系统评价和荟萃分析。
BMC Public Health. 2024 May 6;24(1):1244. doi: 10.1186/s12889-024-18748-8.
6
A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults.一项评估 RSV 预融合 F 蛋白 mRNA 疫苗在健康年轻和老年成年人中的安全性和免疫原性的 1 期、随机、安慰剂对照研究。
Hum Vaccin Immunother. 2021 May 4;17(5):1248-1261. doi: 10.1080/21645515.2020.1829899. Epub 2020 Oct 29.
7
Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge.表达野生型或融合前呼吸道合胞病毒（RSV）融合蛋白的副流感病毒5可保护小鼠和棉鼠免受RSV攻击。
J Virol. 2017 Sep 12;91(19). doi: 10.1128/JVI.00560-17. Print 2017 Oct 1.
8
Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.候选疫苗表达的呼吸道合胞病毒预融合F蛋白诱导的中和抗体反应增强
J Virol. 2015 Sep;89(18):9499-510. doi: 10.1128/JVI.01373-15. Epub 2015 Jul 8.
9
Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany.二价呼吸道合胞病毒预融合F疫苗在德国老年人中预防呼吸道合胞病毒的成本效益
Expert Rev Vaccines. 2025 Dec;24(1):1-10. doi: 10.1080/14760584.2024.2436183. Epub 2024 Dec 18.
10
Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.设计并鉴定一种具有更好稳定性的融合糖蛋白疫苗用于预防呼吸道合胞病毒
Vaccine. 2018 Dec 18;36(52):8119-8130. doi: 10.1016/j.vaccine.2018.10.032. Epub 2018 Oct 16.
本文引用的文献
1
The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age.呼吸道合胞病毒预融合F蛋白疫苗可减轻60岁及以上成年人突破性感染中呼吸道合胞病毒相关疾病的严重程度。
Influenza Other Respir Viruses. 2024 Feb 3;18(2):e13236. doi: 10.1111/irv.13236. eCollection 2024 Feb.
Zotero 插件